Intravitreal Anti–Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Use

To model Medicare Part B and patient savings associated with increased bevacizumab payment and use for intravitreal anti–vascular endothelial growth factor (VEGF) therapy. Cost analysis. Intelligent Research in Sight (IRIS®) Registry data. Medicare claims and IRIS® Registry data were used to calcula...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Minn.), 2020-12, Vol.127 (12), p.1688-1692
Hauptverfasser:	Glasser, David B., Parikh, Ravi, Lum, Flora, Williams, George A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - economics Bevacizumab - economics Cost Savings - economics Fee-for-Service Plans - economics Health Expenditures Intravitreal Injections Medicare Part B - economics Ranibizumab - economics Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins - economics Registries United States Vascular Endothelial Growth Factor A - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!